Abstract
PURPOSE: Levamisole in combination with 5-fluorouracil is an effective adjuvant for the treatment of resected Dukes stage C colon cancer. Since the mechanism of action of levamisole is not known, we have investigated its effects on hepatic and splenic reticuloendothelial system (RES) activity in the rat and compared the effect of levamisole with other known RES stimulators. METHODS: The hepatic and splenic uptake of an intravenous dose of technetium-99m-sulfur colloid has been used to measure RES activity in rats treated with levamisole, glucan, zymosan, chlormethiazole, octreotide, and saline. RESULTS: Levamisole significantly increased the hepatic uptake of technetium-99m-sulfur colloid and is comparable in its effect to the other RES stimulators. In contrast, levamisole has no effect on splenic RES activity. CONCLUSION: RES function is considered to be a potentially important factor in the development of liver metastases, and the stimulatory effect of levamisole on the hepatic RES may partly explain its efficacy as an adjuvant treatment in colon cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Silverberg E, Lubera JA. Cancer statistics 1989. CA 1989;39:3–20.
Gilbert JM. Adjuvant chemotherapy of large bowel cancer. Cancer Treat Rev 1982;9:195–228.
Higgins GA. Current status of adjuvant therapy in the treatment of large bowel cancer. Surg Clin North Am 1983;63:137–50.
Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer: why we still don't know. JAMA 1988;259:3571–8.
Moertel CG, Fleming TR, MacDonald JS,et al. Levamisole and fluorouracil for surgical adjuvant therapy of colon carcinoma. N Engl J Med 1990;322:352–8.
Arnaud JP, Buyse M, Nordlinger B. Adjuvant therapy of poor prognosis colon cancer with levamisole: results of an EORTC double blind randomised clinical trial. Br J Surg 1989;76:284–9.
Renoux G. The general immunopharmacology of levamisole. Drugs 1980;19:89–99.
Tripodi D, Parks LC, Brugmans J. Drug induced restoration of cutaneous delayed hypersensitivity in anergic patients with cancer. N Engl J Med 1978;289:354–7.
Morimoto C, Abe T, Homma M. Restoration of T-cell function in aged mice with long term administration of levamisole. Clin Immunol Immunopathol 1979;12:316–22.
Modig J. Indications of chlormethiazole as a protective agent in experimental endotoxaemia. Eur Surg Res 1988;20:195–204.
Baxter JN, Jenkins SA, Day DW, Shields R. Effects of a somatostatin analogue (SMS 2:01-995) on hepatic and splenic reticulo-endothelial function in the rat. Br J Surg 1985;72:1005–8.
Jenkins SA, Ellenbogen S, Baxter J, Shields R. Sandostatin (SMS) in the long term management of portal hypertension — a preliminary prospective randomised controlled clinical trial. HPB Surg 1992;5 (Suppl):29.
Riggi SJ, Di Luzio NR. Identification of the reticulo-endothelial stimulatory agent in zymosan. Am J Physiol 1961;200:297–300.
Praaning-van Dalen DP, Brouwer A, Knook DL. Clearance capacity of rat liver kupffer, endothelial, and parenchymal cells. Gastroenterology 1981;81:1036–44.
Gomi K, Morimoto M, Normoto K. Cytotoxic T-cell mediated anti-tumor effect of levamisole against murine syngeneic fibrosarcoma. Cancer Res 1982;42:4197–202.
Weese JL, Gilbertson EM, Syrjala SE, Starling JR. Prevention of rat colon cancer metastases by perioperative immunostimulation. Surgery 1984;96:420–6.
Stefan AM, Gendrault JL, McCuskey RS,et al. Phagocytosis, an unrecognized property of murine endothelial liver cells. Hepatology 1986;6:830–36.
Williams DL, Sherwood ER, McNamee RB,et al. Chemoimmunotherapy of experimental hepatic metastases. Hepatology 1987;7:1296–1304.
Davies N, Yates J, Kynaston H,et al. Sandostatin inhibits the growth of two animal models of colorectal liver metastases in the rat. Br J Surg 1992;79(Suppl):S33.
Davies N, Kynaston H, Yates J,et al. Manipulation of the Reticuloendothelial system: effects on the growth of liver tumour. Gut 1992;33(Suppl 1):S47.
Roh MS, Wang L. Kupffer cell (KC) an d hepatic natural killer cells (NK) control the growth ofin vivo liver metastases (abstr). Proc Assoc Acad Surg 1988;22:91.
Roh Ms, Wang L, Oyedeji C,et al. Human Kupffer cells are cytotoxic against human colon adenocarcinoma. Surgery 1990;108:400–5.
Johnkoski JA, Hsueh CT, Doerr RJ, Cohen SA. Augmentation of the immune response of the murine liver by levamisole. Am J Surg 1992;163:202–7.
Redondo JM, Lopen-Guerrero JA, Fresno M. Potentiation of interleukin -2 activity by levamisole and imidazole. Immunol Lett 1987;14:111–6.
Curran RD, Billiar RT, West MA,et al. Effect of interleukin 2 on Kupffer cell activation. Arch Surg 1988;123:1374–8.
Neoptolemos JP, Wood P, Everson NW, Bell PR. The effect of surgical procedures on monocyte function in patients with carcinoma of the colon and rectum. Surg Gynecol Obstet 1986;163:235–42.
Eilber FR, Morton DL. Impaired immunologic reactivity and recurrence folowing cancer surgery. Cancer 1970;25:362–7.
Chretien PB, Catalona WJ, Twomey PL, Sample WF. Correlation of immune reactivity and clinical status in cancer. Ann Clin Lab Sci. 1974;4:331–8.
Windle R, Bell PRF, Shaw D. Five year results of a randomised trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer. Br J Surg 1987;74:569–72.
Jansen PA. The levamisole story. Proc Drug Res 1976;20:347–83.
Guminska M, Kedryna T, Marchut E. Effect of levamisole on energy metabolism in Ehrlrich ascities tumour cellsin vitro. Biochem Pharmacol 1986;35:4369–74.
Author information
Authors and Affiliations
Additional information
The work was funded by Grant 9021310 CA from the Medical Research Council.
Read at the meeting of The American Society of Colon and Rectal Surgeons, San Francisco, California, June 7 to 12, 1992
About this article
Cite this article
Davies, N., Kynaston, H., Yates, J. et al. Reticuloendothelial stimulation: Levamisole compared. Dis Colon Rectum 36, 1054–1058 (1993). https://doi.org/10.1007/BF02047299
Issue Date:
DOI: https://doi.org/10.1007/BF02047299